Boston Scientific (BSX) Upgraded to “B” at TheStreet

Boston Scientific (NYSE:BSX) was upgraded by equities researchers at TheStreet from a “c+” rating to a “b” rating in a research note issued to investors on Thursday.

A number of other analysts have also recently commented on the company. BMO Capital Markets restated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research report on Tuesday, December 12th. Canaccord Genuity dropped their price target on Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, November 29th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Friday, October 20th. Finally, Needham & Company LLC upgraded Boston Scientific from a “buy” rating to a “strong-buy” rating and boosted their price target for the stock from $25.04 to $32.00 in a research report on Friday, December 8th. Two research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $31.00.

Boston Scientific (BSX) traded up $0.25 during trading on Thursday, hitting $27.65. The stock had a trading volume of 10,024,400 shares, compared to its average volume of 10,862,131. The stock has a market capitalization of $37,560.00, a PE ratio of 45.33, a PEG ratio of 1.98 and a beta of 0.96. Boston Scientific has a 1-year low of $23.29 and a 1-year high of $29.93. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.31. The business had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The business’s revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.27 earnings per share. equities analysts forecast that Boston Scientific will post 1.25 EPS for the current fiscal year.

In other Boston Scientific news, SVP David A. Pierce sold 5,152 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $27.00, for a total transaction of $139,104.00. Following the transaction, the senior vice president now owns 38,116 shares of the company’s stock, valued at $1,029,132. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David A. Pierce sold 8,763 shares of the business’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $27.74, for a total value of $243,085.62. Following the transaction, the senior vice president now directly owns 24,201 shares in the company, valued at approximately $671,335.74. The disclosure for this sale can be found here. Insiders have sold 96,585 shares of company stock worth $2,578,197 in the last three months. 0.74% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its stake in shares of Boston Scientific by 106.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 9,898 shares of the medical equipment provider’s stock valued at $245,000 after purchasing an additional 5,100 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Boston Scientific by 349.9% in the 4th quarter. State of Alaska Department of Revenue now owns 177,300 shares of the medical equipment provider’s stock valued at $4,393,000 after purchasing an additional 137,890 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $873,000. Schwab Charles Investment Management Inc. lifted its stake in shares of Boston Scientific by 4.0% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 4,909,075 shares of the medical equipment provider’s stock valued at $121,696,000 after purchasing an additional 187,773 shares during the last quarter. Finally, National Pension Service lifted its stake in shares of Boston Scientific by 2.7% in the 4th quarter. National Pension Service now owns 1,205,485 shares of the medical equipment provider’s stock valued at $29,884,000 after purchasing an additional 31,539 shares during the last quarter. 90.42% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/22/boston-scientific-bsx-upgraded-to-b-at-thestreet.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply